Company News

10/26/2023

Ceres Nanosciences Establishes Five New Wastewater-Based Epidemiology Centers of Excellence Under NIH RADx Initiative

Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of five new wastewater-based epidemiology centers of excellence at the Houston Health Department, Morgan State University, the Nebraska Public Health Laboratory, the State Hygienic Laboratory at the University of Iowa, and the

10/25/2023

BIO-CAT, Inc. Celebrates 35 Years of Innovation, Growth, and Excellence in Enzymes and Probiotics

In 1988, Ed Schuler and his son, Chris Schuler, along with their business associate, Brian Huffman, embarked on a remarkable journey by founding BIO-CAT, Inc. in Keswick, Virginia. Operating out of Ed’s house and Brian’s barn, they began their venture with a single 20-kilogram blender, a few exhaust fans to control dust, and a small shed

10/24/2023

ivWatch Announces Federal Distribution Agreement with Marathon Medical Corp.

ivWatch, LLC, the IV safety company, today announced it has entered into a distribution agreement with Marathon Medical Corp., a medical supply distribution company and service-disabled veteran-owned small business (SDVOSB) focused on providing a range of medical products to Federal healthcare agencies. ivWatch’s patient monitoring technology helps protect patients from unpredictable IV complications with early

10/24/2023

LumaCyte Launches New Compact Radiance® Instrument for Advanced Therapy Biomanufacturing & QC Environments

LumaCyte, a leading innovator in advanced single cell analysis technology and instrumentation, is proud to announce the launch of their newly redesigned flagship Radiance® instrument to meet growing demand for Laser Force Cytology™ (LFC) precision analytics in space-constrained biomanufacturing facilities. The half-sized compact design is new, occupying only 16 inches of bench space, but the

10/24/2023

ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company focused on harnessing the power of the immune system to address life-threatening diseases, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 2 clinical trial of RLS-0071 in patients with acute exacerbations

10/23/2023

EDA Announces Major Regional Tech Hub Wins for Virginia

The U.S. Economic Development Administration (EDA) selected two projects in Virginia as part of the first phase of EDA’s Regional Tech Hubs Program. The Tech Hubs Program, made possible by the CHIPS and Science Act, bipartisan legislation strongly supported by both senators, aims to strengthen U.S. economic and national security by investing in regions across the country that